ADH1A and neoplasm: The therapy group was treated with TILs, IFN-γ and intraperitoneal bolus injections of ADH-1 (200 mg/kg) 5 days a week44 and control groups were also included (PC3 tumor cells, PC3 tumor cells with ADH-1, PC3 tumor cells with IFN-γ, PC3 tumor cells with IFN-γ and ADH-1, PC3 tumor cells with TILs, and PC3 tumor cells with TILs and IFN-γ).